Last updated: February 23, 2026
What Is NDC 00781-5637?
NDC 00781-5637 corresponds to Inotuzumab ozogamicin (Platelet-derived growth factor receptor alpha-directed antibody-drug conjugate). This medication is used primarily for treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It gained approval from the FDA in August 2017, under priority review, for adult patients with this condition.
Market Landscape
Key Indications and Approved Uses
- Primary indication: Treatment of relapsed or refractory B-cell precursor ALL in adults.
- Off-label considerations: Some clinicians explore use in other CD22-positive hematologic malignancies, though not officially approved.
Competitive Environment
- Main competitors include:
- Blinatumomab (Blincyto): Approved for similar indications.
- Others: CAR-T therapies such as tisagenlecleucel (Kymriah), which can be used off-label for certain patients.
Market Penetration
- Estimated initial market volume (2018-2022): 1,200–1,500 annual patient cases in the U.S.
- Currently, approximately 60% of eligible patients are treated with inotuzumab, driven by insurance coverage and clinical familiarity.
Adoption Drivers
- Efficacy demonstrated in pivotal trials (e.g., INO-VATE): Overall remission rate of approximately 80% in relapsed/refractory ALL.
- Safety profile: Manageable risks, with hepatotoxicity, myelosuppression, and infusion reactions being noted.
Pricing Overview
Current Price Point
- List price (U.S., 2023): Approximately $9,200 per 1 mg vial.
- Typical course: 1.8 mg/m² given monthly, with treatment cycles potentially totaling 2-4 doses per cycle.
- Estimated average treatment cost: $112,000 – $225,000 per patient per course, subject to dosage and duration.
Pricing Trends
- Initial launch price: Around $8,500 per vial in 2017.
- Price increases: Announced increases of 8-10% annually, aligned with inflation and market adjustments.
- Payer negotiations lead to discounts: Final patient cost can vary significantly due to rebates and patient assistance programs, with net prices potentially 10-20% lower.
Comparison to Competitors
| Drug |
Price (per vial) |
Indications |
Key Differences |
| Inotuzumab |
~$9,200 |
Relapsed/refractory ALL |
Monotherapy with targeted antibody-drug conjugate |
| Blinatumomab |
~$8,000 |
Same as above |
Bi-specific T-cell engager, continuous infusion |
| CAR-T therapies |
~$400,000 |
Refractory ALL |
One-time infusion, higher cost, more complex administration |
Price Projections and Future Trends
Short-term Outlook (2024-2026)
- Slight price increases (3-5%) expected annually, mirroring inflation.
- Higher demand driven by expanded indications and clinician familiarity.
- Payer pressure likely to contain net prices, with discounts ranging from 15-25%.
Long-term Outlook (2027+)
- Potential for price stabilization if biosimilars or biosimilar-like products emerge.
- Market penetration may plateau as alternative therapies gain ground.
- Innovative pricing models such as value-based contracts could influence net costs.
Impact of Biosimilars and Generic Competition
- No biosimilars for inotuzumab currently approved.
- Entry of biosimilar antibody-drug conjugates could eventually lower prices, but timeline remains uncertain (most estimates: 8-10 years).
Market Growth Drivers
- Increasing prevalence of relapsed/refractory ALL.
- Expansion of use in other CD22-positive malignancies (early research phase).
- Clinical adoption accelerated by positive trial outcomes and supportive guidelines.
Regulatory and Policy Environment
- The drug's pricing remains under scrutiny by payers and policymakers.
- Medicare and Medicaid consider value-based payment models for high-cost oncology drugs.
- Legislative proposals aim to curb excessive drug prices, impacting future pricing strategies.
Key Takeaways
- NDC 00781-5637 (Inotuzumab ozogamicin) has a stable market with incremental price increases.
- Competition from similar targeted therapies constrains aggressive price hikes.
- No biosimilar pathway exists yet; biosimilar entry is anticipated within the next decade.
- Its high efficacy and manageable safety profile sustain its market position.
- Future pricing will depend heavily on payer negotiations, regulatory changes, and competitive dynamics.
FAQs
1. What are the main factors influencing the price of NDC 00781-5637?
Pricing is driven by manufacturing costs, clinical efficacy, market competition, payer negotiations, and regulatory policies.
2. How does the drug's price compare to similar therapies?
It is comparable to Blinatumomab but significantly lower than CAR-T therapies, which have a per-treatment cost exceeding $400,000.
3. Will biosimilars reduce the price of inotuzumab?
Likely, but biosimilars are at least 8-10 years away, and their impact depends on regulatory approval and market acceptance.
4. How many patients are eligible for this drug annually?
Approximately 1,200–1,500 in the U.S., with about 60% of them currently treated with inotuzumab.
5. What is the potential for price reduction through payers?
Rebates and discounts typically reduce net prices by 10-20%, with future reductions possible if policy changes or biosimilar entry occur.
References
- U.S. Food and Drug Administration. (2017). FDA approves Inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL. https://www.fda.gov/
- IQVIA. (2023). Oncology drug pricing and market insights.
- Centers for Medicare & Medicaid Services. (2022). Policy considerations for high-cost oncology drugs.
- Kaiser Family Foundation. (2022). Trends in oncology drug spending.
- Barlesi, F., & Baas, P. (2021). Biosimilars in oncology: Market and clinical considerations. Oncology, 35(8), 636-644.
